MorphoSys and Cherry Biolabs Announce Licensing of Hemibody Technology
Accesswire
*The parties signed a multi-target exclusive licensing agreement for application of Cherry Biolabs' Hemibody technology..
Cancer Cells May Hibernate Like “Bears” to Evade Chemo Treatments
Advertisement
Related news coverage
-
PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-Oncology
GlobeNewswire
-
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer
GlobeNewswire
-
Global Gene Therapy Market Report 2020-2027: Market is Projected to Reach a Revised $3.3 Billion
GlobeNewswire
-
Global Gene Therapy Industry
GlobeNewswire
You might like
More coverage
Sunway University's Collaboration with Harvard Medical School Makes Advances in Potential Cancer Treatment using Gene Therapy
PR Newswire Asia
KUALA LUMPUR, Malaysia, Aug. 26, 2020 /PRNewswire/ --* *Sunway University's Professor Jeff Tan Kuan Onn of the Department of..
-
MorphoSys and Cherry Biolabs Announce licensing of Hemibody Technology
EQS Group
-
CytoDyn Completes Second Non-dilutive $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Help Expedite License Applications Here and Abroad and Successful COVID-19 Trials
GlobeNewswire
-
Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights
GlobeNewswire
-
Onxeo Reports its Financial Results for the First Half of 2020 and Provides an Update on its Activities
GlobeNewswire